^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:adavosertib (AZD1775) (WEE1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck

    Excerpt:
    ...- International normalized ratio (INR) 50%) p53 mutated HNSCC patients at the MTD...
    Trial ID:
    NCT02508246
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Clin Cancer Res
    Title:

    Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer

    Excerpt:
    p53-mutant HNSCC cell lines were sensitive to small-molecule inhibitors targeting WEE1...The WEE1 kinase inhibitor, MK-1775 had the broadest and most significant effect on cell survival in both primary and recurrent/metastasis-derived HNSCC cells, with an IC50 ranging from 220 nmol/L to 3.1 μmol/L...The IC50 for MK-1775 in p53 mutant PCI-15A and PCI-15B HNSCC cells (0.14–0.17 μmol/L)...
    DOI:
    10.1158/1078-0432.CCR-13-2858